Nexoplex Bio is developing next-generation vaccines for cancer. Nexoplex’s approach seeks to generate potent and durable immune responses by leveraging insights into the immune system’s ability to recognize and destroy diseased cells by targeting select antigens.
Gritstone Bio is now Nexoplex Bio
After emerging from Chapter 11 bankruptcy, hiring a new management team and a dedicated new team of scientists, Gritstone bio is changing its name to Nexoplex bio. This change is reflective of new energy and focus on the development of our portfolio of bispecific antibodies. Watch for more exciting updates as our team progresses our portfolio of bispecifics to provide treatments for unmet needs in oncology.